Allergan PLC. (AGN) Shares Bought by Bradley Foster & Sargent Inc. CT
Bradley Foster & Sargent Inc. CT grew its stake in shares of Allergan PLC. (NYSE:AGN) by 326.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 34,739 shares of the company’s stock after purchasing an additional 26,586 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Allergan PLC. were worth $8,445,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of AGN. Veritas Asset Management LLP purchased a new stake in shares of Allergan PLC. during the 1st quarter worth $761,339,000. Iridian Asset Management LLC CT boosted its position in shares of Allergan PLC. by 141.3% in the 1st quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock worth $306,733,000 after buying an additional 751,848 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Allergan PLC. in the 1st quarter worth about $124,255,000. Blue Ridge Capital L.L.C. boosted its position in shares of Allergan PLC. by 24.1% in the 1st quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock worth $456,313,000 after buying an additional 370,400 shares in the last quarter. Finally, Harbour Capital Advisors LLC boosted its position in shares of Allergan PLC. by 21,412.3% in the 2nd quarter. Harbour Capital Advisors LLC now owns 345,917 shares of the company’s stock worth $1,423,000 after buying an additional 344,309 shares in the last quarter. Institutional investors own 82.02% of the company’s stock.
Several equities research analysts recently commented on AGN shares. Royal Bank Of Canada reiterated a “buy” rating and issued a $285.00 price objective on shares of Allergan PLC. in a research report on Wednesday, September 6th. BidaskClub lowered shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Deutsche Bank AG reiterated a “buy” rating and issued a $273.00 price objective (up from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Wells Fargo & Company reiterated an “outperform” rating and issued a $280.00 price objective (up from $270.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. Finally, Credit Suisse Group set a $288.00 price objective on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Saturday, August 5th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $273.34.
Allergan PLC. (NYSE:AGN) opened at 202.66 on Friday. The firm has a market cap of $67.75 billion, a P/E ratio of 6.17 and a beta of 1.18. The stock’s 50 day moving average is $229.79 and its 200-day moving average is $236.07. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same period last year, the company posted $3.35 EPS. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. Analysts forecast that Allergan PLC. will post $16.26 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were given a dividend of $0.70 per share. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.33%. Allergan PLC.’s payout ratio is presently 9.95%.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.